RCS - Ondine Biomedical - Two Abstracts Accepted at World Congress

Ondine Biomedical

22/04/2026 07:00

RNS Number : 3909B

Ondine Biomedical Inc.

22 April 2026

 

22 April 2026

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine Biomedical Announces Selection of Two Abstracts for Presentation at the 2026 World Congress on Infectious Diseases

Ondine Biomedical Inc. (LON: OBI), a leader in photodisinfection-based therapies, is pleased to announce that two of its abstracts have been accepted for poster presentation at the upcoming World Congress on Infectious Diseases, taking place 25-27 June 2026 in Barcelona, Spain.

The abstracts highlight the long-term clinical and economic impact of Ondine's light-activated antimicrobial technology in surgical settings. Notably, the presentations will feature 8-year longitudinal data demonstrating the technology's improved outcomes compared to traditional antibiotic treatments.

One of the featured presentations, Breaking the Mupirocin Paradox: Light Activated Nasal Decolonization Achieves 66% SSI Reduction and Sustained Cost Savings Without Resistance Signals in Spine Surgery over 8 Years, underscores the efficacy of nasal photodisinfection in highly complex surgical environments over many years with no evidence of generating resistance. The study details how the non-antibiotic approach successfully mitigates issues associated with antibiotic resistance while maintaining a significant reduction in Surgical Site Infections ("SSIs").

The second abstract, The Double Whammy of Cardiac SSI Under-Reporting: Correcting Incidence and Inflation to Unlock Capacity and Eradicate AMR Debt, addresses limitations in infection control caused by using unadjusted cost data and short-term SSI rates. This practice understates costs and impact, potentially limiting necessary changes for improved outcomes.

Carolyn Cross, CEO of Ondine Biomedical, emphasised the clinical significance of these findings:

"Nasal photodisinfection has demonstrated sustained reductions in SSI rates over many years without any observed loss of efficacy. This represents a key advantage of our light-activated, non-antibiotic antimicrobial therapy over topical antibiotics. By avoiding the development of antimicrobial resistance associated with traditional treatments, we are providing a durable solution for patient safety in highly complex surgical environments."

The World Congress on Infectious Diseases is a global platform for clinicians and researchers to share breakthroughs in combating antimicrobial resistance and hospital-acquired infections. Ondine's research will be presented in the Poster Presentation (Virtual) category, allowing for broad international engagement with the findings.

 

Enquiries:

Ondine Biomedical Inc.
www.ondinebio.com
Carolyn Cross, CEO
+1 604 669 0555
 or via 5654 & Company
Strand Hanson Limited (Nominated & Financial Adviser)
James Harris, Richard Johnson
+44 (0)20 7409 3494
Peel Hunt LLP (Broker & Joint Financial Adviser)
James Steel, Dr. Chris Golden
+44 (0)20 7418 8900
5654 & Company (Financial PR and IR Adviser)
ondinebiomedical@5654.co.uk
Matthew Neal, Chris Gardner, Melissa Gardiner
+44 0791 7800 011
+44 0775 7697 357

 

About the World Congress on Infectious Diseases (Infection 2026)

The 10th Edition of the World Congress on Infectious Diseases (Infection 2026) is a premier hybrid forum dedicated to the theme "New Frontiers in Infectious Diseases: Diagnosis, Treatment, and Control." Hosted at the Hotel Alimara, the congress serves as a global meeting point for infectious disease specialists, clinical researchers, and public health leaders to address the most pressing challenges in global health. The program features a comprehensive scientific agenda, including keynote lectures and interactive sessions that bridge the gap between foundational research and cutting-edge technological innovations, particularly in the fields of antimicrobial resistance and disease prevention.

 

About Steriwave and its Mode of Action

Steriwave nasal photodisinfection is a non-invasive and painless treatment that uses a proprietary light-activated photosensitive agent to destroy harmful bacteria, viruses, and fungi-including antibiotic-resistant strains-in the nasal passages. The procedure takes five minutes and, unlike antibiotics, is effective immediately and allows the normal nasal microbiome to recover quickly, without fostering antimicrobial resistance.

The two-step process involves applying the Steriwave formulation in the nostrils where it electrostatically binds to microbes rather than human cells. The area is then illuminated with safe red light to activate the formulation, triggering an oxidative burst that physically destroys all manner of pathogens within minutes. This rapid and overwhelming oxidative stress makes it extremely difficult for pathogens to develop resistance, and the process stops immediately once the light is turned off. Steriwave has been used in a growing number of Canadian hospitals since 2011.

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's Steriwave photodisinfection system has a CE mark in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRADZGZDMMKGVZZ